Nanoscope CEO to Present at H.C. Wainwright Conference Amid Key Regulatory Milestones — Nanoscope Therapeutics Inc.

Event summary

Nanoscope Therapeutics CEO Sulagna Bhattacharya to present at H.C. Wainwright Global Investment Conference on September 14, 2026.
FDA has accepted and filed Nanoscope's BLA for MOGENRY, its lead optogenetic therapy for retinitis pigmentosa (RP).
Company plans to initiate Phase 3 trial for Stargardt disease in 2026, following positive Phase 2 results.
MCO-010 has received multiple regulatory designations, including FDA Fast Track, Orphan Drug, and RMAT for Stargardt disease.

The big picture

Nanoscope's participation in the H.C. Wainwright conference comes at a critical juncture, with its lead candidate MOGENRY under FDA review and expanding clinical programs in multiple retinal diseases. The company's optogenetic approach, which bypasses the need for genetic testing and invasive surgery, positions it uniquely in a field increasingly focused on precision medicine. Success here could validate the company's platform technology and attract further investment as it seeks to address a broad range of retinal degenerative conditions.

What we're watching

Regulatory Approval: Whether the FDA will approve MOGENRY for retinitis pigmentosa, potentially making it the first optogenetic therapy for this indication.
Clinical Development: The pace at which Nanoscope advances its Phase 3 trial for Stargardt disease and other indications like geographic atrophy and Leber congenital amaurosis.
Market Positioning: How Nanoscope positions MOGENRY against emerging competitors in the retinal degeneration space, particularly as a disease-agnostic therapy.